tipifarnib has been researched along with cimadronate in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (cimadronate) | Trials (cimadronate) | Recent Studies (post-2010) (cimadronate) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 105 | 3 | 4 |
| Protein | Taxonomy | tipifarnib (IC50) | cimadronate (IC50) |
|---|---|---|---|
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.1863 | |
| Farnesyl pyrophosphate synthase | Leishmania donovani | 0.16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashihara, E; Fuchida, S; Inaba, T; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R; Yamada, N | 1 |
1 other study(ies) available for tipifarnib and cimadronate
| Article | Year |
|---|---|
Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Humans; Multiple Myeloma; Quinolones; Tumor Cells, Cultured | 2005 |